Collectively, SKP1 copy number losses (shallow and deep deletions) range from 7% to 44% in prostate and ovarian cancers, respectively, while CUL1 and RBX1 losses range from 2% (glioblastoma) to 23% (head and neck) and 10% (prostate) to 80% (ovarian), respectively. Here, RBX1 is linked to glioblastoma.